1862. Time to Therapeutic Goal is Faster with Continuous Infusion Vancomycin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. (15th December 2022)

• Record Type: Journal Article
• Authors: Gilliam, Diari; Acosta, Dominic; Carvour, Martha; Walraven, Carla
• Is Part Of: Open forum infectious diseases. Volume 9:(2022)Supplement 2
• Publication Date: 2022-12-15
• Subjects: Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofac492.1491
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Continuous infusion vancomycin (CIV) is an attractive alternative to intermittent infusion vancomycin (IIV) as it may result in more rapid attainment of target serum drug concentrations, provide ease of monitoring, and decreased risk of nephrotoxicity. At our institution CIV has been the preferred infusion method for over 20 years. The purpose of this study was to examine the time to therapeutic goal among patients receiving IIV compared to CIV for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. Secondary objectives included all-cause readmission, relapse, and mortality 30 days after completion of therapy. Methods: This was a single-center, retrospective study of patients who received vancomycin for MRSA bacteremia between January 2018 and December 2021. Included patients were ≥ 18 years of age, had ≥ 1 blood culture positive for MRSA, received vancomycin for > 10 days, and had follow-up in the outpatient parenteral antimicrobial therapy clinic. Patients who were pregnant, received vancomycin for ≤ 10 days, or were diagnosed at an outside hospital were excluded. All patients were started on IIV then transitioned to CIV. Patients on IIV with an appropriately drawn trough between 15-20 mcg/mL were considered therapeutic. For patients on CIV, a single random level between 17-25 mcg/mL, corresponding to an AUC/MIC of 400-600 mcg·h/mL, was considered therapeutic. Results: Sixty-three patients with 65 MRSA bacteremia episodes were included. Significantly fewer patients achieved a therapeutic goal on IIV compared to patients on CIV (52.3% vs. 83.1%, p-value < 0.01). Of the 31 patients who did not reach the IIV trough goal, 87.1% became therapeutic when switched to CIV. Patients on IIV took 3.6 days, on average, to reach the target goal, compared to 1.9 days when patients were switched to CIV (95% confidence interval 0.50 – 2.96, p-value < 0.01). No patients experienced relapse or mortality 30 days after completion of therapy. Six patients (9.2%) were readmitted 30 days after completion of therapy. Conclusion: CIV enabled patients with MRSA bacteremia to achieve the AUC/MIC goal significantly faster than when receiving IIV. Patients who were unable to achieve a therapeutic goal on IIV became therapeutic once switched to CIV. Disclosures: Martha Carvour, MD, PhD, The Suga Project/The Suga Project Foundation: I provide consultation and support but do not receive compensation.